Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 7, 2007, Pages 884-889

  Phumala Morales, Noppawan ^a   Cherlermchoung, Chalermkhwan ^a   Fucharoen, Suthat ^b   Chantharaksri, Udom ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

thalassemia; Lipoprotein; Oxidative stress; Paraoxonase; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; HEMOGLOBIN E; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; BETA-THALASSEMIA; CHOLESTEROL, LDL; FEMALE; HEMOGLOBIN E; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; OXIDATIVE STRESS;

EID: 34447263737     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.145     Document Type: Article

References (38)

1. Fucharoen S, Winichagoon P, Pootrakul P, Piankijagum A, Wasi P. Variable severity of Southeast Asian β-thalassemia/hemoglobin E diseases. Birth Defects 1987;23:241-8.
2. Weatherall DJ, Clegg JB. The thalassemia syndrome, 3rd ed. Oxford: Blackwell Scientific, 1981.
3. Sonakul D, Fucharoen S. Pulmonary thrombembolism in thalassemic patients. South East Asian J Trop Med Public Health 1992;23:25-8.
4. Sonakul D, Suwanagool P, Sirivaidyapong P, Fucharoen S. Distribution of pulmonary thrombembolism lesions in thalassemic patients. Birth Defects 1988;23:375-84.
5. Wong V, Yu Y, Laing R, Tso W, Li A, Chan TK. Cerebral thrombosis in β-thalassemia/hemoglobin E disease. Stroke 1990;21:812-6.
6. Pascher F, Keen R. Ulcer legs in Cooley's anemia. N Engl J Med 1957;256:1220-2.
7. Supeenun U, Laoharungpanya N, Phumala N, Sipankapracha P, Pootrakul P, Fucharoen S, et al. The effect of vitamin E on platelet activity in β-thalassemia patients. Br J Haematol 2003;123:738-44.
8. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001;80:577-83.
9. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, et al. Alteration in vascular endothelial cell-related plasma proteins in thalassemic patients and their correlation with clinical symptoms. Thromb Haemost 1995;74:1045-9.
10. Livrea MA, Tesoriere L, Maggio A, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low density lipoprotein and atherogenetic risk in beta-thalassemia. Blood 1998;92:3936-42.
11. Brizzi P, Isaja T, D'Agata A, Malaguarnera L, Malaguarnera M, Musumeci S. Oxidized LDL antibodies (OLAB) in patients with β-thalassemia major. J Atheroscl Thromb 2002;9:139-44.
12. Luechapudiporn R, Morales NP, Fucharoen S, Chantharaksri U. The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in β-thalassemia/Hb E. Clin Chem Lab Med 2006;44:574-81.
13. Li H-L, Liu D-P, Liang C-C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003;81:766-79.
14. Arrol S, Mackness MI, Durrington PN. High-density lipoprotein associated enzymes and the prevention of low density lipoprotein oxidation. Eur J Lab Med 1996;4:33-8.
15. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis 2002;3(Suppl):49-55.
16. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003;42:93-114.
17. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase: a potent new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-9.
18. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoproteinassociated phospholipase A2, platelet activating factor acetylhydrolase. Atherosclerosis 2002;3(Suppl):57-68.
19. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, action and therapeutic applications. Shock 2004;21:210-21.
20. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepsis AD. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long term therapy with erythropoietin. Nephrol Dial Transplant 2006;21:1270-7.
21. Kamisako T, Takeuchi K, Ito T, Tamaki S, Kosaka T, Adachi Y. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemia hepatobiliary disease. Hepatol Res 2003;26:23-7.
22. Tsironis LD, Katsouras CS, Lourida ES, Mitsisos JV, Goudevenos J, Elisf M, et al. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004;177:193-201.
23. Winichagoon P, Fucharoen S, Cen P, Wasi P. Genetic factors affecting clinical severity in β-thalassemia syndromes. J Pediatr Hematol Oncol 2000;22:573-80.
24. Ordovas JM, editor. Lipoprotein protocols, methods in molecular biology, Vol 110. Totowa, NJ: Humana Press, 1998.
25. Asakawa T, Matsushita S. Coloring condition of thiobarbituric acid test for detecting lipid hydroperoxide. Lipids 1980;15:137-40.
26. International Committee for Standardization in Hematology (ICSH). Recommendation for measurement for total and unsaturated iron binding capacity in serum, recommendation for measurement of serum iron in human blood. Br J Haematol 1978;38:281-94.
27. Gowri MS, Van der Westhuyzen DR, Bridges S, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999;19:2226-33.
28. Aarsman AJ, Neys FW, Van den Bosch H. Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activating factor acetylhydrolase. Eur J Biochem 1991;200:187-93.
29. Brites FD, Verona J, Schreier LE, Fruchart J-C, Castro GR, Wikinski RL. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004;35:235-40.
30. Ferretti G, Bacchetti T, Negre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structure modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7.
31. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 2003;37:77-83.
32. Ece A, Atamer Y, Gurkan F, Davutoglu M, Bilici M, Tutanc M, et al. Paraoxonase, antioxidant response and oxidative stress in children with chronic renal failure. Pediatr Nephrol 2006;21:239-45.
33. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004;89:2957-62.
34. Moldoveanu E, Tanaseanu C, Tanaseanu S, Kosaka T, Manea G, Marta DS, et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Int Med 2006;17:38-42.
35. Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007;26:342-8.
36. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron overloaded patients with beta-thalassemia or sickle cell disease. Br J Haematol 2006;135:254-63.
37. Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hydrocholesterolemia. J Lipid Res 2002;43:256-63.
38. Chi-Chen G, Kane JP, Hamilton RL. Thermal behavior of cores of human serum triglyceride-rich lipoproteins: a study of induced circular dichroism of β-carotene. Biochemistry 1984;23:1119-24.